The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Relapse after HSCT 2021 | The use of DLI to prevent relapse
Christoph Schmid, MD, University of Augsburg, Augsburg, Germany, comments on the use of donor lymphocyte infusion (DLI) in relapse management. Dr Schmid reports that results from the PRO-DLI Phase II prospective trial (NCT02856464), assessing whether prophylactic donor DLI improves the disease-free survival of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), are eagerly awaited. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
Disclosures
Christoph Schmid, MD, has received research and travel grants from Novartis, Roche, Abbvie and Neovii; honoraria and speakers bureau from Novartis, Roche, BMS and Eurocept; and is also on the advisory boards of Novartis, Daichii, Eurocept and Roche.
